The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors.
Pierre Fumoleau
Consultant or Advisory Role - Debiopharm Group
Jean-Charles Soria
No relevant relationships to disclose
Jean-Pierre Delord
Consultant or Advisory Role - Debiopharm Group
Riccardo Belli
Employment or Leadership Position - Debiopharm Group
Silvano Brienza
Employment or Leadership Position - Debiopharm Group
Claudio Zanna
Employment or Leadership Position - Debiopharm Group
Alice Destaillats
Employment or Leadership Position - Debiopharm Group
Consultant or Advisory Role - Debiopharm Group
Elisabeth Rouits
Employment or Leadership Position - Debiopharm Group
Antoine Hollebecque
No relevant relationships to disclose
Anas Gazzah
No relevant relationships to disclose
Nicolas Isambert
No relevant relationships to disclose